Want to see STAA full AI Analyst Report?
STAA Stock Chart & Stats
$23.38
-$0.28(-1.20%)
At close: 4:00 PM EDT
$23.38
-$0.28(-1.20%)
Day’s Range― - ―
52-Week Range$15.59 - $35.87
Previous CloseN/A
Volume242.83K
Average Volume (3M)784.05K
Market Cap
$1.21B
Enterprise Value$902.09
Total Cash (Recent Filing)$163.89M
Total Debt (Recent Filing)$37.29M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 12, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding49,788,494
10 Day Avg. Volume1,088,807
30 Day Avg. Volume784,046
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)3.40
Price to Sales (P/S)4.89
P/FCF Ratio-29.21
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.50Price Target Upside30.45% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)0.71
Revenue Forecast (FY)$334.26M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Low LeverageLow leverage and a sizable equity base give STAAR durable financial flexibility to fund operations, scale Nidau manufacturing, absorb seasonal cash swings, and invest in distribution or product launches without immediate refinancing pressure. This reduces solvency risk while the business normalizes cash flow.
High Gross Margins And Product EconomicsSustained gross margins near the mid-70s indicate strong unit economics for ICL lenses, reflecting manufacturing and product differentiation advantages. High gross margins create headroom to cover R&D, sales expansion, and manufacturing scale costs, supporting long-term margin recovery if unit volumes stabilize.
Operational Turnaround, Product Expansion And Manufacturing ScaleA rapid revenue rebound, swing to positive adjusted EBITDA, expanded FDA indication and the Nidau supply plan are structural: they expand addressable market, reduce tariff exposure, and create scalable production to meet demand. Together these support durable revenue and profitability improvement as adoption grows.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flow increases execution risk: it can deplete cash reserves, constrain investments in commercialization or manufacturing, and force reliance on existing cash, asset sales, or equity issuance. Durable cash generation must return for self-funded growth.
High Geographic Concentration In ChinaRelying on one market for ~50% of sales creates structural exposure to regional regulatory shifts, geopolitical disruptions, or local competitive entrants. Even with Nidau supply benefits, concentration can produce volatile top-line outcomes and complicates consistent global growth planning.
Sustained Pricing Pressure And Inventory/manufacturing HeadwindsHigh single-digit ASP declines plus higher-cost inventory roll-through and prior low production volumes create margin volatility risk. Even with strong gross margins today, persistent pricing pressure and legacy inventory costs could erode sustainable margins and slow profit conversion from revenue growth.
STAA FAQ
What was Staar Surgical Company’s price range in the past 12 months?
Staar Surgical Company lowest stock price was $15.59 and its highest was $35.87 in the past 12 months.
What is Staar Surgical Company’s market cap?
Staar Surgical Company’s market cap is $1.21B.
When is Staar Surgical Company’s upcoming earnings report date?
Staar Surgical Company’s upcoming earnings report date is Aug 12, 2026 which is in 7 days.
How were Staar Surgical Company’s earnings last quarter?
Staar Surgical Company released its earnings results on May 13, 2026. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.054 by $0.356.
Is Staar Surgical Company overvalued?
According to Wall Street analysts Staar Surgical Company’s price is currently Undervalued.
Does Staar Surgical Company pay dividends?
Staar Surgical Company does not currently pay dividends.
What is Staar Surgical Company’s EPS estimate?
Staar Surgical Company’s EPS estimate is 0.23.
How many shares outstanding does Staar Surgical Company have?
Staar Surgical Company has 49,788,494 shares outstanding.
What happened to Staar Surgical Company’s price movement after its last earnings report?
Staar Surgical Company reported an EPS of $0.41 in its last earnings report, beating expectations of $0.054. Following the earnings report the stock price went up 8.878%.
Which hedge fund is a major shareholder of Staar Surgical Company?
Currently, no hedge funds are holding shares in STAA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Staar Surgical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$30.50 (30.45% Upside)
$30.50 (30.45% Upside)
Blogger Sentiment
Bullish
STAA Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 574.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.37%
Trailing 12-Months
Company Description
Staar Surgical Company
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
STAA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strong operational and financial turnaround in Q1 2026 highlighted by very strong revenue growth (+119.6% YoY), a return to profitability (adjusted EBITDA $24.4M), improved gross margins (73.6% vs. 65.8%), normalized distributor inventories in China, product launches (EVO+), and scalable Swiss manufacturing to avoid tariffs. Management emphasized cost discipline and a clearer path to sustainable profitability. Offsetting factors include geopolitical and regional headwinds (Middle East, India), near-term pricing pressure (ASP down high single digits), some lingering inventory and higher-cost product roll-through impacts, and conservative disclosure (no formal guidance) due to macro uncertainty and limited near-term visibility. Overall, the positive operational and financial momentum materially outweighs the listed challenges, though dependence on China and macro risks warrant continued monitoring.View all STAA earnings summariesSTAA Stock 12 Month Forecast
Average Price Target
$30.50
▲(30.45% Upside)











